Theralase advances Ruvidar® trials for bladder and other cancers, targeting NDA submissions by 2026, launching multiple Phase I/II studies, seeking US listing, and pursuing international partnerships for commercialization and research collaboration.

Theralase® presented interim Phase II data showing Ruvidar™’s strong safety and efficacy in treating BCG-unresponsive bladder cancer, with durable complete responses, no serious drug-related adverse events, and potential for regulatory approval in 2026.

Theralase® announces Ruvidar™ inhibits Deubiquitinating Enzymes (DUBs), a key factor in cancer and drug resistance. This dual action—blocking DUBs and inducing oxidative stress—makes Ruvidar™ a promising cancer therapy candidate.

Theralase® reported a slight revenue decline in 2024 but reduced net loss, advanced clinical trials for cancer and Parkinson’s treatments, showed promising results in HSV and lymphoma studies, and plans FDA resubmissions.

Theralase® validated University of Manitoba research showing Ruvidar™ is safe and effective against HSV-1. Topical treatment healed lesions in four days, supporting its potential as a herpes therapeutic and clinical candidate.

Theralase® validated Ruvidar™ as safe and effective against HSV-1 in mice, with complete lesion healing in four days, supporting its potential for clinical use and advancement toward human trials.

Theralase® announced University of Manitoba research showing Ruvidar™ is more effective than acyclovir in inhibiting HSV-1 post-infection, even without light, and offers enhanced antiviral effects in combination therapy.

Theralase®’s bladder cancer treatment data was selected for podium presentation at the 2025 AUA Annual Meeting. Interim results show strong safety and efficacy, supporting Ruvidar™ as a breakthrough therapy option.

V.TLT | December 9, 2024 Associated Medical Professionals of NY, Urology of Indiana and Central Ohio Urology Group are the latest three US-based study sites for clinical research of Theralase®’s bladder cancer treatment TORONTO, ON / December 9, 2024 / Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has launched three new US-based Clinical Study Sites (“CSSs“) for its bladder cancer registrational clinical study; specifically: Associated Medical Professionals of NY (Syracuse, New York), Urology of Indiana (Greenwood, Indiana) and Central Ohio Urology Group (Gahanna, Ohio). The Principal Investigators (“PIs“) for the Theralase® clinical study at the new CSSs are as follows: Associated Medical Professionals of NY – Ilija Aleksic, MD Dr. … Read More

V.TLT | December 5, 2024 St. Joseph’s Healthcare Hamilton is the latest Canadian clinical study site for clinical investigation of Theralase®’s Anti-Cancer Therapy for the treatment of bladder cancer TORONTO, ON / December 5, 2024 / Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has launched a new Clinical Study Site (“CSS“) for its bladder cancer clinical study; specifically, St. Joseph’s Healthcare Hamilton (Hamilton, Ontario, Canada). Theralase®’s lead drug, RuvidarTM (TLD-1433), activated by the TLC-3200 Medical Laser System (“TLC-3200“) is currently under clinical investigation in Canada and the United States in a Phase II registration study for Bacillus Calmette-Guérin (“BCG“)-Unresponsive Non-Muscle Invasive Bladder Cancer (“NMIBC“) Carcinoma In-Situ (“CIS“) with or without resected … Read More